Avalo Therapeutics Inc. held its 2025 Annual Meeting on June 17, 2025. During the meeting, stockholders voted to elect eight nominees to the Board, all of whom were successfully elected. Additionally, a "Say-on-Pay" resolution regarding the compensation of named executive officers was approved. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-031818), on June 17, 2025, and is solely responsible for the information contained therein.